Select therapeutic use:
Indications for ADIPEX-P:
Short-term monotherapy as adjunct in management of exogenous obesity in patients with initial body mass ≥30kg/m2, or ≥27kg/m2 in presence of other risk factors.
>16yrs: 37.5mg once daily before or 1–2 hrs after breakfast, or 18.75mg 1–2 times daily. Avoid late evening dosing.
≤16yrs: not recommended.
Arteriosclerosis. Cardiovascular disease. Hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs.
Discontinue if dyspnea, angina pectoris, syncope, lower extremity edema or other symptoms of primary pulmonary hypertension occur. Discontinue after a few weeks as tolerance to anorectic effect occurs. Diabetes. Prescribe limited supply to prevent overdose. Pregnancy (Cat.C). Nursing mothers: not recommended.
Hypertensive crisis with MAOIs. Concomitant SSRIs: not recommended. Avoid alcohol. Blocks guanethidine. Monitor antidiabetic agents. Possible risk of valvular heart disease with fenfluramine.
CNS overstimulation, dizziness, palpitations, arrhythmias, hypertension, psychosis, dry mouth, GI disturbances, urticaria, impotence, primary pulmonary hypertension, and/or regurgitant cardiac valvular disease.
Caps—100; Tabs—100, 1000